Ratings eHealth, Inc.

Equities

EHTH

US28238P1093

Real-time Estimate Cboe BZX 01:39:59 2024-05-03 pm EDT 5-day change 1st Jan Change
4.695 USD +2.07% Intraday chart for eHealth, Inc. +3.31% -46.33%

Strengths

  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.17 for the 2024 fiscal year.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Multiline Insurance & Brokers

1st Jan change Capi. Investor Rating ESG Refinitiv
-46.33% 134M
C-
-4.06% 60.9B
C
+5.71% 52.12B
B-
+4.59% 25.81B
C+
+17.07% 23.63B
C
+25.12% 9.33B -
+17.57% 6.29B -
+2.59% 2B
C+
+13.70% 1.8B
C-
-21.94% 1.49B
C-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes